Early treatment risks are outweighed by possibility of prolonged period of durable response, ODAC says of J&J's CAR-T in earlier lines of multiple myeloma treatment. • Source: Shutterstock
Learn what's happening at the US FDA. On the go.
Derrick Gingery and the team bring you a weekly "Drug Fix".
